DCM
CBIO

Driehaus Capital Management’s Crescent Biopharma CBIO Stock Holding History

Driehaus Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-302,457
Closed -$3.59M – 395
2025
Q4 		$3.59M Hold
302,457
– – 0.02% 317
2025
Q3 		$3.6M Hold
302,457
– – 0.03% 335
2025
Q2 		$4.88M Buy
+302,457
New +$6.4M 0.04% 304
2014
Q3 		– Sell
-605
Closed -$510K – 563
2014
Q2 		$510K Sell
605
-1,769
-75% -$1.76M 0.02% 504
2014
Q1 		$3.88M Buy
+2,374
New +$2.87M 0.12% 215

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Driehaus Capital Management's CBIO Position: Q1 2026 in Review

Driehaus Capital Management sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 302,457 shares — an estimated $3.59M sold.

Driehaus Capital Management first reported a position in CBIO in Q1 2014 and held it in 5 quarters. The position peaked at $4.88M in Q2 2025. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Driehaus Capital Management reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Driehaus Capital Management sold 302,457 Crescent Biopharma shares in Q1 2026, an estimated $3.59M.
  • Driehaus Capital Management first reported a position in Crescent Biopharma in Q1 2014 and held it in 5 quarters.
  • Driehaus Capital Management's Crescent Biopharma position peaked at $4.88M in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.